UBS Group
CSTL icon

UBS Group’s Castle Biosciences CSTL Stock Holding History

UBS Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Sell
49,163
-92,710
-65% -$3.04M ﹤0.01% 5403
2025
Q4 		$5.52M Sell
141,873
-149,489
-51% -$4.82M ﹤0.01% 3922
2025
Q3 		$6.63M Sell
291,362
-72,486
-20% -$1.47M ﹤0.01% 3740
2025
Q2 		$7.43M Buy
363,848
+315,089
+646% +$5.83M ﹤0.01% 3438
2025
Q1 		$976K Sell
48,759
-763,841
-94% -$18.9M ﹤0.01% 5300
2024
Q4 		$21.7M Buy
812,600
+758,466
+1,401% +$23.1M ﹤0.01% 2236
2024
Q3 		$1.54M Buy
54,134
+5,411
+11% +$138K ﹤0.01% 4246
2024
Q2 		$1.06M Sell
48,723
-6,120
-11% -$136K ﹤0.01% 4374
2024
Q1 		$1.21M Buy
54,843
+13,366
+32% +$291K ﹤0.01% 4444
2023
Q4 		$895K Buy
41,477
+23,436
+130% +$412K ﹤0.01% 4597
2023
Q3 		$305K Buy
18,041
+736
+4% +$12.9K ﹤0.01% 5041
2023
Q2 		$237K Buy
17,305
+6,731
+64% +$136K ﹤0.01% 5368
2023
Q1 		$240K Buy
10,574
+89
+0.8% +$2.17K ﹤0.01% 5251
2022
Q4 		$247K Buy
10,485
+3,354
+47% +$77.8K ﹤0.01% 5289
2022
Q3 		$186K Sell
7,131
-9,094
-56% -$255K ﹤0.01% 5154
2022
Q2 		$356K Buy
16,225
+12,376
+322% +$288K ﹤0.01% 4523
2022
Q1 		$173K Sell
3,849
-6,549
-63% -$271K ﹤0.01% 5476
2021
Q4 		$446K Buy
10,398
+9,142
+728% +$478K ﹤0.01% 5065
2021
Q3 		$83K Buy
1,256
+576
+85% +$40.5K ﹤0.01% 5954
2021
Q2 		$50K Sell
680
-8,497
-93% -$561K ﹤0.01% 6428
2021
Q1 		$628K Sell
9,177
-1,966
-18% -$148K ﹤0.01% 4695
2020
Q4 		$748K Buy
11,143
+7,121
+177% +$386K ﹤0.01% 4252
2020
Q3 		$206K Sell
4,022
-2,229
-36% -$99.2K ﹤0.01% 4779
2020
Q2 		$236K Sell
6,251
-432
-6% -$14.8K ﹤0.01% 4680
2020
Q1 		$199K Buy
6,683
+1,490
+29% +$45K ﹤0.01% 4727
2019
Q4 		$178K Buy
5,193
+2,383
+85% +$58.3K ﹤0.01% 5671
2019
Q3 		$51K Buy
+2,810
New +$62.3K ﹤0.01% 6189

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's CSTL Position: Q1 2026 in Review

UBS Group reduced its Castle Biosciences (CSTL) stake by 65% in Q1 2026, selling an estimated $3.04M and leaving 49,163 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #5403.

UBS Group first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $21.7M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • UBS Group held 49,163 shares of Castle Biosciences worth $1.21M as of Q1 2026.
  • UBS Group sold 92,710 Castle Biosciences shares in Q1 2026, an estimated $3.04M.
  • Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5403 holding.
  • UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.